Clinical trial
Study to Evaluate the Response to and Safety of an 8-Day Course of Phenoptin™…
NCT00104260 · BioMarin Pharmaceutical, Industry · Completed
Key facts
| NCT number | NCT00104260 |
|---|---|
| Title | Study to Evaluate the Response to and Safety of an 8-Day Course of Phenoptin™ Treatment in Subjects With Phenylketonuria |
| Official title | A Phase 2, Multicenter, Open-Label Study to Evaluate the Response to and Safety of an 8-Day Course of Phenoptin™ Treatment in Subjects With Phenylketonuria Who Have Elevated Phenylalanine Levels |
| Lead sponsor | BioMarin Pharmaceutical, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Phenylketonurias |
| Intervention type | Drug |
| Interventions | sapropterin dihydrochloride |
| Enrollment | 700 |
| Start date | Dec 1, 2004 |
| Completion | Nov 1, 2005 |
| First posted | Feb 25, 2005 |
| Last update posted | Apr 9, 2007 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: